- Home
- GPRO vs DSGN Comparison
GPRO vs DSGN Comparison
Compare GPRO & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRO
- DSGN
- Stock Information
- Founded
- GPRO 2004
- DSGN 2017
- Country
- GPRO United States
- DSGN United States
- Employees
- GPRO N/A
- DSGN N/A
- Industry
- GPRO Industrial Machinery/Components
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- GPRO Consumer Discretionary
- DSGN Health Care
- Exchange
- GPRO Nasdaq
- DSGN Nasdaq
- Market Cap
- GPRO 194.6M
- DSGN 208.9M
- IPO Year
- GPRO 2014
- DSGN 2021
- Fundamental
- Price
- GPRO $1.49
- DSGN $6.45
- Analyst Decision
- GPRO
- DSGN
- Analyst Count
- GPRO 0
- DSGN 0
- Target Price
- GPRO N/A
- DSGN N/A
- AVG Volume (30 Days)
- GPRO 9.1M
- DSGN 184.3K
- Earning Date
- GPRO 08-11-2025
- DSGN 11-06-2025
- Dividend Yield
- GPRO N/A
- DSGN N/A
- EPS Growth
- GPRO N/A
- DSGN N/A
- EPS
- GPRO N/A
- DSGN N/A
- Revenue
- GPRO $746,731,000.00
- DSGN N/A
- Revenue This Year
- GPRO N/A
- DSGN N/A
- Revenue Next Year
- GPRO $9.72
- DSGN N/A
- P/E Ratio
- GPRO N/A
- DSGN N/A
- Revenue Growth
- GPRO N/A
- DSGN N/A
- 52 Week Low
- GPRO $0.40
- DSGN $2.60
- 52 Week High
- GPRO $2.37
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- GPRO 55.12
- DSGN 73.57
- Support Level
- GPRO $1.43
- DSGN $4.92
- Resistance Level
- GPRO $1.58
- DSGN $5.68
- Average True Range (ATR)
- GPRO 0.15
- DSGN 0.42
- MACD
- GPRO -0.01
- DSGN 0.08
- Stochastic Oscillator
- GPRO 44.29
- DSGN 93.90
About GPRO GoPro Inc.
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.